Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Mar 23;18(3):e0283246.
doi: 10.1371/journal.pone.0283246. eCollection 2023.

Cross-sectional study to describe allergic rhinitis flare-ups and associated airways phenotype in house dust mite sensitization

Ludovic de Gabory  1 , Sabine Amet  2 , Annelore Le Maux  2 , Jean-Pierre Meunier  3 , Antoine Chartier  2 , Cécile Chenivesse  4
Affiliations
Observational Study

Cross-sectional study to describe allergic rhinitis flare-ups and associated airways phenotype in house dust mite sensitization

Ludovic de Gabory et al. PLoS One. .

Abstract

Objectives: To quantify and describe flare-ups of house dust mite allergic rhinitis (HDM-AR) which had occurred during the last 12 months in a population of adults and children candidate for Allergen ImmunoTherapy (AIT). Next, to identify associated clinical features.

Materials and methods: This was an observational, multicenter, cross-sectional study that included patients aged ≥ 5 years with HDM-AR eligible for AIT and without prior AIT for at least 12 months. Flare-ups were all period with impairment of quality of life (QoL) and requiring a change in their usual treatment. Data were collected using medical records and patient questionnaires. Variables associated with the occurrence of ≥ 2 AR flare-ups were identified.

Results: 1,701 patients were included (average age: 23 years, 51.5% males, 30.4% children, 17.7% adolescents and 51.9% adults). Severe and persistent AR affected 70.9% of them and 53.7% showed polysensitization. Asthma was associated with AR in 34.4% and was well-controlled in 58.5%. The occurrence of at least one AR flare-up in the year was reported by 77.7%, with an annual rate in the whole population of 2.6 ± 3.9 and a duration of 14.1 ± 17.1 days. Deeply or moderately AR-related degraded QoL was experienced by 39.5% and 64.6%, respectively. The occurrence of ≥ 2 AR flare-ups was reported by 54.5% and was associated with polysensitization, AR intermittence and severity.

Conclusion: AR flare-ups are frequent and impair QoL in HDM-allergic patients, suggesting that it could be considered as therapeutic targets.

PubMed Disclaimer

Conflict of interest statement

Ludovic de Gabory: Honoraria/Consulting: ALK-SAS, AstraZeneca, Chiesi, GlaxoSmithKline, Integra Life Science, Laboratoire de la Mer, Laboratoire Chemineau, Medtronic, Sanofi Genzyme, Zambon. Sabine Amet: ALK SAS corporate employee Annelore Le Maux: ALK SAS corporate employee Jean-Pierre Meunier: Manager of the CRO Axonal, which was designated by ALK to conduct the trial Antoine Chartier: ALK SAS corporate employee Cécile Chenivesse: Grants from AstraZeneca, Santelys Personal fees from ALK SAS, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Sanofi-Regeneron, TEVA Congress support from ALK SAS, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKlein, Novartis, Pierre Fabre, Pfizer, Roche, TEVA

Figures

Fig 1
Fig 1. Flow chart of study population.
Fig 2
Fig 2. Frequency of AF flare-ups by month.
See this image and copyright information in PMC

References

    1. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al.. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010. Sep;126(3):466–76. doi: 10.1016/j.jaci.2010.06.047 - DOI - PubMed
    1. Shin YS, Jung CG, Park HS. Prevalence and clinical characteristics of local allergic rhinitis to house dust mites. Curr Opin Allergy Clin Immunol. 2018. Feb;18(1):10–15. doi: 10.1097/ACI.0000000000000413 - DOI - PubMed
    1. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004. Nov;24(5):758–64. doi: 10.1183/09031936.04.00013904 - DOI - PubMed
    1. Demoly P, Broué-Chabbert A, Wessel F, Chartier A. Severity and disease control before house dust mite immunotherapy initiation: ANTARES a French observational survey. Allergy Asthma Clin Immunol. 2016. Apr 11;12:13. doi: 10.1186/s13223-016-0119-z - DOI - PMC - PubMed
    1. Gayraud J, Refabert L, Chartier A. Influence of asthma on specific immunotherapy practices in patients with house dust mite-induced allergy. An observational study AdArA. Rev Fr Allergol. 2013. Sep;53(5):458–467. 10.1016/j.reval.2013.07.003. - DOI

Publication types